Marshall Wace在Q2中收购了362 690个Novavax股份,而该公司却错过了Q2 EPS的预期。 Marshall Wace acquired 362,690 Novavax shares in Q2, while the company missed Q2 EPS expectations.

Marshall Wace LLP 在第二季度收购了 362,690 股 Novavax（纳斯达克股票代码：NVAX），价值约 459 万美元，机构对此产生了浓厚的兴趣，其中 53.04% 的股份由此类投资者持有。 Marshall Wace LLP acquired 362,690 shares of Novavax (NASDAQ: NVAX) worth approximately $4.59 million in Q2, amid strong institutional interest, with 53.04% of shares held by such investors. Novavax报告,Q2 EPS为0.99美元,预期损失为1.82美元。 Novavax reported a Q2 EPS of $0.99, missing expectations of $1.82. 其市场上限为17.3亿美元,52周的价格为3.53至23.86美元。 Its market cap is $1.73 billion, with a 52-week price range of $3.53 to $23.86. 分析师的评级喜忧参半，一致认为“持有”，平均目标价为 15.80 美元。 Analysts show mixed ratings, with a consensus "Hold" and an average price target of $15.80.